AbbVie (ABBV) Given a $84.00 Price Target by BMO Capital Markets Analysts

BMO Capital Markets set a $84.00 price target on AbbVie (NYSE:ABBV) in a report issued on Thursday. The firm currently has a hold rating on the stock.

Several other analysts have also weighed in on ABBV. Vetr lowered AbbVie from a strong-buy rating to a buy rating and set a $113.08 price objective for the company. in a report on Monday, January 8th. Barclays restated a hold rating and issued a $68.00 price objective on shares of AbbVie in a report on Thursday, September 28th. Evercore ISI restated an outperform rating and issued a $100.00 price objective (up previously from $95.00) on shares of AbbVie in a report on Saturday, September 30th. Piper Jaffray Companies restated a buy rating on shares of AbbVie in a report on Tuesday, January 2nd. Finally, Jefferies Group restated a buy rating and issued a $107.00 price objective on shares of AbbVie in a report on Thursday, September 28th. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. AbbVie has an average rating of Buy and a consensus price target of $100.94.

Shares of AbbVie (NYSE:ABBV) traded up $1.07 during mid-day trading on Thursday, reaching $100.34. The company’s stock had a trading volume of 4,370,600 shares, compared to its average volume of 4,460,000. The company has a quick ratio of 1.32, a current ratio of 1.45 and a debt-to-equity ratio of 5.08. AbbVie has a one year low of $59.27 and a one year high of $101.28. The firm has a market cap of $159,950.00, a price-to-earnings ratio of 24.35, a PEG ratio of 1.18 and a beta of 1.53.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company had revenue of $7 billion during the quarter, compared to analyst estimates of $7 billion. During the same quarter in the previous year, the firm posted $1.21 EPS. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. analysts predict that AbbVie will post 5.55 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.83%. This is an increase from AbbVie’s previous quarterly dividend of $0.64. The ex-dividend date is Thursday, January 11th. AbbVie’s dividend payout ratio is currently 68.93%.

In other news, EVP Michael Severino sold 25,633 shares of the company’s stock in a transaction on Friday, November 10th. The stock was sold at an average price of $94.69, for a total transaction of $2,427,188.77. Following the completion of the sale, the executive vice president now directly owns 114,922 shares of the company’s stock, valued at $10,881,964.18. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Henry O. Gosebruch sold 18,300 shares of the company’s stock in a transaction on Monday, October 30th. The shares were sold at an average price of $90.55, for a total value of $1,657,065.00. Following the transaction, the insider now directly owns 81,287 shares in the company, valued at $7,360,537.85. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 494,676 shares of company stock valued at $47,237,938. 0.23% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of ABBV. Jennison Associates LLC acquired a new position in AbbVie during the third quarter valued at $544,418,000. Capital International Investors raised its position in AbbVie by 137.7% during the third quarter. Capital International Investors now owns 7,854,929 shares of the company’s stock valued at $697,989,000 after buying an additional 4,550,954 shares during the period. Vanguard Group Inc. raised its position in AbbVie by 3.3% during the second quarter. Vanguard Group Inc. now owns 115,920,673 shares of the company’s stock valued at $8,405,409,000 after buying an additional 3,706,941 shares during the period. Janus Henderson Group PLC raised its position in AbbVie by 1,949.7% during the second quarter. Janus Henderson Group PLC now owns 3,833,535 shares of the company’s stock valued at $277,967,000 after buying an additional 3,646,510 shares during the period. Finally, Orbis Allan Gray Ltd increased its position in AbbVie by 35.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 12,704,919 shares of the company’s stock worth $921,233,000 after purchasing an additional 3,340,038 shares during the last quarter. 69.18% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/01/14/abbvie-abbv-given-a-84-00-price-target-by-bmo-capital-markets-analysts.html.

AbbVie Company Profile

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Analyst Recommendations for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply